Proposal for MK-4007 (MedKoo Biosciences catalog #345998)

Below is a comprehensive evaluation of MK-4007 as a potential therapeutic candidate for Polycystic Ovary Syndrome (PCOS).

Overview of Therapeutic Candidate:
MK-4007 is a small molecule inhibitor specifically targeting protein tyrosine phosphatase 1B (PTP1B). This compound belongs to the class of PTP1B inhibitors, which were developed using rational medicinal chemistry approaches to overcome the challenges associated with targeting the highly conserved and polar active site of PTP1B. Historically, early PTP1B inhibitors were designed as phosphotyrosine mimetics, using acidic functional groups to occupy the catalytic pocket; however, these compounds often suffered from low cell permeability and poor pharmacokinetics. To resolve these issues, drug discovery efforts have shifted towards compounds that target both the active site and allosteric pockets outside the catalytic domain, as this strategy has led to improved selectivity and oral bioavailability. MK-4007 is described as a potent competitive inhibitor that has been optimized for cell permeability and oral bioavailability, with demonstrable preclinical efficacy in diabetic rodent models (ClinicalTrials.gov, n.d.; Zhang & Zhang, 2007; Maccari & Ottanà, 2023). Its design is consistent with other successful examples from the class—including compounds like trodusquemine—where structural modifications have enabled selective inhibition of PTP1B without severely compromising the druglike properties required for in vivo activity (Zhang & Zhang, 2007; Maccari & Ottanà, 2023).

Therapeutic History:
PTP1B inhibitors as a drug class have primarily been explored for the treatment of metabolic diseases such as type 2 diabetes mellitus (T2DM) and obesity. Preclinical studies have demonstrated that inhibition or genetic deletion of PTP1B leads to enhanced insulin signaling, improved glucose homeostasis, and resistance to diet-induced obesity. Mouse models lacking PTP1B exhibit enhanced insulin sensitivity, increased energy expenditure, and resistance to weight gain, which has provided strong proof-of-concept for the therapeutic modulation of this enzyme (Zhang & Zhang, 2007; Maccari & Ottanà, 2023). Several small molecule inhibitors, as well as antisense oligonucleotides targeting PTP1B, have reached early clinical trials with a focus on metabolic endpoints; although none have yet received regulatory approval, the safety and translational feasibility have been supported by extensive pharmacokinetic and pharmacodynamic (PK/PD) studies in diabetic rodent models (Boonloh et al., 2020; Delibegović et al., 2024).

In terms of repurposing for PCOS, the rationale stems from the established link between insulin resistance and PCOS pathogenesis. While the direct clinical usage of PTP1B inhibitors is predominantly oriented toward diabetes and obesity, there is a considerable body of literature suggesting that disrupted insulin signaling in ovarian granulosa cells contributes to the metabolic and reproductive dysfunction seen in PCOS (Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012). Notably, data from Open Targets indicate a modest association of the PTPN1 gene (encoding PTP1B) with PCOS; however, preclinical insights suggest that even a limited alteration in PTP1B activity in ovarian tissue could have a significant impact on insulin receptor (IR) signaling (Ochoa et al., 2023; Diamanti-Kandarakis & Dunaif, 2012). Therefore, the therapeutic history of PTP1B inhibitors in metabolic diseases provides a promising background for their potential repurposing in PCOS, despite there being no direct prior clinical studies of MK-4007 in PCOS patients.

Mechanism of Action:
The central role of PTP1B in insulin signaling underpins the rationale for using MK-4007 in conditions of insulin resistance. Under normal physiological conditions, insulin binds its receptor (a heterotetramer consisting of two extracellular α-subunits and two transmembrane β-subunits with intrinsic tyrosine kinase activity), leading to autophosphorylation of specific tyrosine residues on the β-subunit. This autophosphorylation event is critical for the subsequent recruitment and phosphorylation of insulin receptor substrates (IRS-1, IRS-2, etc.). The phosphorylated IRS proteins then serve as docking sites for PI3K (phosphatidylinositol 3-kinase), which activates the Akt/PKB signaling cascade, culminating in the translocation of the GLUT4 glucose transporter to the cell surface and thereby promoting glucose uptake into insulin-sensitive tissues (Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012).

PTP1B acts as a basal negative regulator by dephosphorylating the activated insulin receptor as well as key downstream substrates, essentially acting as a “brake” on the insulin signal transduction pathway. By removing phosphate groups, PTP1B reduces the activation of the PI3K/Akt pathway and thereby impairs GLUT4 translocation – a defect that is a hallmark of insulin resistance in many tissues. MK-4007, by inhibiting the catalytic activity of PTP1B, would prevent this dephosphorylation and thereby enhance or prolong the phosphorylated, active state of the insulin receptor and IRS proteins (Zhang & Zhang, 2007; Maccari & Ottanà, 2023).

More specifically, MK-4007 is designed to act as a competitive inhibitor, binding to the active site of PTP1B and occluding the access of the natural phosphotyrosine substrates. In doing so, it preserves the tyrosine phosphorylation status of the insulin receptor and IRS proteins. The subsequent activation of the PI3K/Akt cascade is expected to result in higher levels of Akt phosphorylation, thereby boosting downstream signaling that leads to increased translocation of GLUT4 to the plasma membrane. This is particularly relevant for ovarian granulosa cells, where impaired insulin signaling has been implicated in abnormal follicular development and steroidogenesis commonly observed in PCOS (Joharatnam, 2012; Diamanti-Kandarakis & Dunaif, 2012).

Moreover, the compound’s reported optimization for cell permeability and oral bioavailability suggests that MK-4007 can effectively enter target cells such as granulosa cells and exert its inhibitory action on intracellular PTP1B. The preclinical efficacy in diabetic rodent models further substantiates its potency in enhancing insulin signaling in vivo, which is promising for its use in conditions characterized by insulin resistance (Zhang et al., 2016; ClinicalTrials.gov, n.d.).

Expected Effect:
The hypothesis behind employing MK-4007 in PCOS is that by inhibiting PTP1B, it will lead to enhanced insulin receptor phosphorylation in ovarian granulosa cells. This molecular action should, in turn, lead to an augmented activation of the PI3K/Akt pathway—a critical signaling axis for both metabolic regulation and cell survival. In granulosa cells affected by the insulin-resistant state often present in PCOS, this enhanced signaling is expected to promote GLUT4 translocation to the cell membrane, thereby increasing glucose uptake and correcting metabolic defects (Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012).

There is supporting evidence from related literature that shows PTP1B inhibition improves insulin sensitivity in peripheral tissues, including those in animal models of diabetes and obesity (Zhang & Zhang, 2007; Maccari & Ottanà, 2023). Although PTP1B gene expression (PTPN1) in ovarian tissues has only a modest direct association with PCOS according to some datasets (Ochoa et al., 2023), the molecular rationale is compelling: even if the gene association is weak, the phosphatase’s biochemical role in dephosphorylating the insulin receptor and its substrates remains central to insulin resistance. Therefore, in in vitro assays using PCOS granulosa cells, treatment with MK-4007 should restore or enhance the tyrosine phosphorylation levels of the insulin receptor, elevate IRS-1 activity, and ultimately increase phosphorylation of Akt. This cascade facilitates the translocation of GLUT4 to the cell surface, potentially alleviating the insulin resistance that contributes to the disordered folliculogenesis and hyperandrogenism observed in PCOS (Joharatnam, 2012; Diamanti-Kandarakis & Dunaif, 2012).

Moreover, given the reported favorable PK/PD and safety data in rodent models, MK-4007 appears well-suited for further investigation. The cellular and animal data from diabetic models provide a strong mechanistic foundation, suggesting that similar insulin-sensitizing effects could be realized in ovarian tissues. The expected outcome in the assay would be a quantifiable increase in insulin receptor and downstream signaling molecule phosphorylation, increased GLUT4 presence at the plasma membrane, and subsequently, enhanced glucose uptake into granulosa cells (Zhang et al., 2016; ClinicalTrials.gov, n.d.).

Overall Evaluation:
Overall, the prospect of repurposing MK-4007 for PCOS treatment is scientifically intriguing and supported by a solid mechanistic basis. Strengths of this therapeutic candidate include:

• The well‐established role of PTP1B in negatively regulating insulin receptor signaling, which provides a clear rationale for why its inhibition would enhance insulin sensitivity. This is particularly important in PCOS, where aberrant insulin signaling contributes not only to metabolic abnormalities but also to reproductive dysfunction (Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012).
• Optimized cell permeability and oral bioavailability, as reported for MK-4007, increase the likelihood that effective drug concentrations are achieved in target tissues following systemic administration (ClinicalTrials.gov, n.d.; Maccari & Ottanà, 2023).
• Preclinical efficacy in diabetic rodent models demonstrates that the drug can enhance insulin receptor phosphorylation and restore downstream signaling cascades, a finding that is directly translatable to granulosa cell function given the similar insulin signaling machinery present across insulin-responsive tissues (Zhang et al., 2016; Boonloh et al., 2020).
• The competitive inhibition of PTP1B by MK-4007 is based on well-understood molecular interactions, which has been supported by structure-based studies and the use of phosphotyrosine mimetics that improve the drug’s potency and selectivity (Zhang & Zhang, 2007; Maccari & Ottanà, 2023).

Yet, several weaknesses or challenges remain:

• Clinical associations between PTPN1 (the gene encoding PTP1B) and PCOS are modest. Data from Open Targets show only a very low overall association score between PTPN1 and PCOS, suggesting that while the mechanistic rationale is sound, the direct genetic link is not robust (Ochoa et al., 2023).
• There is currently no direct clinical or preclinical data available that evaluates MK-4007 specifically in PCOS models or in ovarian granulosa cells. Most of the supportive evidence comes from diabetic rodent models, and while there is a clear mechanistic overlap between insulin resistance in T2DM and PCOS, one must be cautious when extrapolating these results to the ovarian environment (Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012).
• The safety profile, although favorable in rodent models, must be thoroughly evaluated in the context of reproductive tissues, as ovarian cells can be uniquely sensitive to perturbations in metabolic signaling. Furthermore, long-term effects on ovarian steroidogenesis and follicle development will need careful investigation (Ma et al., 2011; Maccari & Ottanà, 2023).
• Finally, the effectiveness of MK-4007 in enhancing GLUT4-mediated glucose uptake in granulosa cells must be specifically assessed, since most of the available data relate to muscle, liver, and adipose tissues. Direct experiments in ovarian cell models (e.g., primary granulosa cells from PCOS patients) are necessary to validate the hypothesis (Joharatnam, 2012; Diamanti-Kandarakis & Dunaif, 2012).

In conclusion, based on the current available literature, MK-4007 demonstrates significant promise as a repurposed therapeutic candidate for PCOS. Its ability to inhibit PTP1B—a key negative regulator of insulin signaling—provides a sound mechanistic rationale for enhancing insulin receptor phosphorylation, augmenting downstream PI3K/Akt pathway activation, and ultimately increasing GLUT4-dependent glucose uptake in insulin-resistant tissues, including ovarian granulosa cells. The strengths of MK-4007 lie in its optimized pharmacokinetic properties, demonstrated preclinical efficacy in metabolic disease models, and a compelling molecular mechanism that is relevant to the insulin signaling defects observed in PCOS. However, further targeted studies are required to assess its specific efficacy and safety in ovarian cells and to establish whether the improvements in insulin signaling translate into meaningful clinical benefits for PCOS patients. These studies should include in vitro experiments using granulosa cells derived from PCOS patients, in vivo studies in PCOS animal models, and eventually carefully designed clinical trials that monitor both metabolic and reproductive endpoints.

Overall, while there is a robust scientific foundation supporting the concept, additional research dedicated to the PCOS context is necessary before proceeding with clinical development. The promise of MK-4007 as a modulator of insulin resistance makes it a candidate worth further investigation, but its ultimate success will depend on demonstrating that restoring insulin signaling in ovarian tissues thereby corrects the metabolic and reproductive abnormalities that characterize PCOS (Zhang & Zhang, 2007; Diamanti-Kandarakis & Dunaif, 2012; Joharatnam, 2012).

References
Boonloh, K., Singdam, P., & Pannangpetch, P. (2020). Update on mechanism of insulin resistance and new trend of drug development. Unknown Journal.

ClinicalTrials.gov. (n.d.). PTP1B inhibitor polycystic ovary syndrome OR insulin resistance OR diabetes OR MK-4007. Retrieved from https://clinicaltrials.gov

Delibegović, M., Dall’Angelo, S., & Dekeryte, R. (2024). Protein tyrosine phosphatase 1b in metabolic diseases and drug development. Nature Reviews Endocrinology, 20, 366–378. https://doi.org/10.1038/s41574-024-00965-1

Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33, 981–1030. https://doi.org/10.1210/er.2011-1034

Joharatnam, J. (2012). Insulin signalling in granulosa cells. Unknown Journal. https://doi.org/10.25560/9784

Ma, Y.-m., Tao, R.-y., Liu, Q., Li, J., Tian, J.-y., Zhang, X.-l., Xiao, Z.-y., & Ye, F. (2011). PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro. Molecular and Cellular Biochemistry, 357, 65–72. https://doi.org/10.1007/s11010-011-0876-4

Maccari, R., & Ottanà, R. (2023). Can allostery be a key strategy for targeting PTP1B in drug discovery? A lesson from trodusquemine. International Journal of Molecular Sciences, 24(9621). https://doi.org/10.3390/ijms24119621

Ochoa, D., et al. (2023). The next-generation Open Targets Platform: Reimagined, redesigned, rebuilt. Nucleic Acids Research.

Zhang, S., & Zhang, Z.-Y. (2007). PTP1B as a drug target: Recent developments in PTP1B inhibitor discovery. Drug Discovery Today, 12, 373–381. https://doi.org/10.1016/j.drudis.2007.03.011

Zhang, X., Tian, J., Li, J., Huang, L., Wu, S., Liang, W., Zhong, L., Ye, J., & Ye, F. (2016). A novel protein tyrosine phosphatase 1B inhibitor with therapeutic potential for insulin resistance. British Journal of Pharmacology, 173, 1939–1949. https://doi.org/10.1111/bph.13483
